SCHEMBL5484208

SCHEMBL5484208

COc1ccccc1-n1c(=O)ccn(Cc2ccc([N+](=O)[O-])cc2)c1=O

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 6/20 0.45
ALDH1A1 P00352 2/20 0.45
LMNA P02545 1/20 0.45
MAPK1 P28482 1/20 0.45
SMN1; SMN2 Q16637 1/20 0.45
APP P05067 4/20 0.42
SNCA P37840 4/20 0.42
MEN1 O00255 2/20 0.42
KMT2A Q03164 2/20 0.42
GFER P55789 1/20 0.42
HTR1A P08908 2/20 0.41
NPC1 O15118 1/20 0.41
CASP3 P42574 1/20 0.41
RAB9A P51151 1/20 0.41
SENP7 Q9BQF6 1/20 0.41
SENP6 Q9GZR1 1/20 0.41
ABCC1 P33527 1/20 0.41
TP53 P04637 1/20 0.40
ADRA1D P25100 2/20 0.40
ADRA1A P35348 2/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5474617 0.77 ALDH1A1 (0.61) MAPTALDH1A1LMNASMN1; SMN2MEN1
SCHEMBL5481632 0.73 P2RX4 (0.52) MAPTALDH1A1SMN1; SMN2MEN1KMT2A
SCHEMBL9453625 0.72 KMT2A (0.54) MAPTALDH1A1LMNASMN1; SMN2MEN1
SCHEMBL11556531 0.72 MAPK1 (0.69) MAPTALDH1A1LMNAMAPK1SMN1; SMN2
SCHEMBL16880622 0.70 P2RX4 (0.52) MAPTALDH1A1LMNASMN1; SMN2MEN1
SCHEMBL5484204 0.70 SMN1; SMN2 (0.48) MAPTALDH1A1LMNAMAPK1SMN1; SMN2
SCHEMBL5800407 0.69 KMT2A (0.44) MAPTALDH1A1LMNASMN1; SMN2MEN1
SCHEMBL5480233 0.68 HTR6 (0.43) MAPTALDH1A1LMNASMN1; SMN2KMT2A
SCHEMBL23296136 0.68 DBH (0.54) MAPTALDH1A1LMNASMN1; SMN2MEN1
SCHEMBL16339690 0.67 JAK2 (0.54) MAPTLMNANPC1TP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070010529-A1 Nitrogenous heterocyclic compounds and medical use thereof ONO PHARMACEUTICAL CO., LTD. (JP) 2007-01-11 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070010529-A1 Nitrogenous heterocyclic compounds and medical use thereof MAPK1, NOS1, NOS2 MAPT 1199/4885ALDH1A1 1694/4885LMNA 2404/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.